Back to top
more

CONMED (CNMD)

(Real Time Quote from BATS)

$74.00 USD

74.00
210,698

-0.76 (-1.02%)

Updated Nov 8, 2024 02:51 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Masimo (MASI) Boosts O3 Platform With Three New Indices

by Zacks Equity Research

Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.

Aurora Cannabis (ACB) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Cannabis revenue growth and improved gross margin are likely to aid Aurora Cannabis (ACB) in Q4 earnings.

Here's Why You Should Retain NextGen Healthcare Stock Now

by Zacks Equity Research

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Here's Why You Should Invest in Integer Holdings (ITGR) Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

What's in Store for Aurora Cannabis (ACB) in Q4 Earnings?

by Zacks Equity Research

Aurora Cannabis (ACB) expects revenues within $100-$107 million in fiscal Q4.

Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.

Here's Why You Should Consider Betting on CONMED Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

What's in the Cards for HealthEquity (HQY) in Q2 Earnings?

by Zacks Equity Research

Higher revenues and possible margin expansion are likely to aid HealthEquity (HQY) in Q2 earnings.

Patterson Companies (PDCO) Earnings Beat Estimates in Q1

by Zacks Equity Research

Patterson Companies' (PDCO) Q1 results benefit from higher revenues, gross margin expansion, solid show by Corporate segment and lower expenses.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Ecolab (ECL) Expands Product Portfolio With New Technology

by Zacks Equity Research

Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

What's in Store for Cooper Companies (COO) in Q3 Earnings?

by Zacks Equity Research

Better-than-expected performance at CVI and CSI and higher revenues are likely to aid Cooper Companies (COO) in Q3 earnings.

CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q2 earnings. However, high long-term debt remains a concern.

Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 5.66% and 2.22%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Conmed (CNMD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LH vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

LH vs. CNMD: Which Stock Is the Better Value Option?

Here's Why You Should Invest in CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues

by Zacks Equity Research

Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.

Medtronic's Titan Spine Buyout to Boost Spine Surgery Range

by Zacks Equity Research

Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.

Walgreens Gains on Strategic Deals, Margin Pressure Remains

by Zacks Equity Research

Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.

Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics

by Zacks Equity Research

The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.